American Association for Cancer Research
Browse
15357163mct200144-sup-238142_3_supp_7305252_qxdh4j.pptx (72.13 kB)

Figure S5 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment

Download (72.13 kB)
figure
posted on 2023-04-03, 18:48 authored by Masakazu Hashimoto, John David Konda, Stephanie Perrino, Maria Celia Fernandez, Andrew M. Lowy, Pnina Brodt

PDAC cells express PD-L1.

Funding

Canadian Institute for Health Research

MITACS

Research Manitoba

Find out more...

MUHC Foundation

MI4 initiative of McGill University

NIH

History

ARTICLE ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy, resistant to chemotherapy and associated with high incidence of liver metastases and poor prognosis. Using murine models of aggressive PDAC, we show here that in mice bearing hepatic metastases, treatment with the IGF-Trap, an inhibitor of type I insulin-like growth factor receptor (IGF-IR) signaling, profoundly altered the local, immunosuppressive tumor microenvironment in the liver, curtailing the recruitment of myeloid-derived suppressor cells, reversing innate immune cell polarization and inhibiting metastatic expansion. Significantly, we found that immunotherapy with anti–PD-1 antibodies also reduced the growth of experimental PDAC liver metastases, and this effect was enhanced when combined with IGF-Trap treatment, resulting in further potentiation of a T-cell response. Our results show that a combinatorial immunotherapy based on dual targeting of the prometastatic immune microenvironment of the liver via IGF blockade, on one hand, and reversing T-cell exhaustion on the other, can provide a significant therapeutic benefit in the management of PDAC metastases.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC